Studies suggested that paclitaxel, either weekly or tri-weekly regimen, followed by FAC achieved pCR between 6%-19% in patients with luminal breast cancers and 30% for estrogen receptor (ER) negative and HER2 negative tumors [1]. This evidence concerns the gene ERBB2 and breast carcinoma.